248282-07-7
248282-07-7 structure
- Name: Laquinimod Sodium Salt
- Chemical Name: sodium,5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate
- CAS Number: 248282-07-7
- Molecular Formula: C19H17ClN2NaO3
- Molecular Weight: 379.79
- Catalog: Signaling Pathways Apoptosis Apoptosis
- Create Date: 2017-02-10 06:54:31
- Modify Date: 2025-08-22 00:37:54
-
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4].
| Name | sodium,5-chloro-3-[ethyl(phenyl)carbamoyl]-1-methyl-2-oxoquinolin-4-olate |
|---|---|
| Synonyms |
Laquinimod sodium (USAN)
Laquinamod SAIK-MS compound TV-5600 Laquinimod sodium LaquiniMod Laquinimod Sodium Salt |
| Description | Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1][2][3][4]. |
|---|---|
| Related Catalog | |
| Target |
NF-κB |
| In Vitro | Laquinimod sodium reverses EAE and inhibits pathogenic T cell immune responses. Laquinimod reverses RR-EAE and inhibits inflammatory T cell responses via a direct effect on myeloid APC. Laquinimod alters myeloid APC subsets and inhibits Th1 and Th17 polarization of myelin-specific T cells. Laquinimod-induced type II (M2) monocytes reverse established EAE[1]. Laquinimod modulates the phenotype of B cells of healthy donors. Laquinimod modulates expression of markers related to regulatory capacity in B cells of RRMS patients. Laquinimod reduces IFNγ cytokine expression in CD4+ T cells[2]. |
| In Vivo | Laquinimod sodium treatment inhibits donor myelin-specific T cells from transferring EAE to naive recipient mice. In vivo laquinimod treatment alters subpopulations of myeloid antigen presenting cells (APC) that include a decrease in CD11c+CD11b+CD4+ dendritic cells (DC) and an elevation of CD11bhiGr1hi monocytes[1]. |
| References |
| Molecular Formula | C19H17ClN2NaO3 |
|---|---|
| Molecular Weight | 379.79 |
| Exact Mass | 378.07500 |
| PSA | 65.37000 |
| LogP | 4.00240 |